Operator: Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Q3 2023 Earnings Conference Call. At this time, participants are in a listen-only mode.
− Achieved Third Quarter 2023 Global Net Product Revenues of $313 Million, Representing 35% Year-Over-Year Growth Compared to Q3 2022 –
− Received Complete Response Letter from U.S. FDA for.
Mackenzie Financial Corp boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 16.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,096 shares of the biopharmaceutical company’s stock after purchasing an additional 4,299 shares […]
Steel Peak Wealth Management LLC lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,017 shares of the biopharmaceutical company’s stock after purchasing an additional 322 shares during […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-one brokerages that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12-month price target among […]